| Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca |
ACTRN12624000039583: Evaluating the effect of Dapagliflozin on Alanine Transaminase Levels in Type 2 Diabetic Patients with Non Alcoholic Fatty Liver Disease |
|
|
| Not yet recruiting | 4 | 192 | | | MTI Lady Reading Hospital, MTI Lady Reading Hospital | Non Alcoholic Steatohepatitis, Type 2 Diabetes Mellitus | | | | |
ACTRN12624000033549: Evaluating the effect of Dapagliflozin on Proteinuria in Type 2 Diabetic Patients. |
|
|
| Not yet recruiting | 4 | 516 | | | MTI Lady Reading Hospital, MTI Lady Reading Hospital | Type 2 Diabetes Mellitus, Kidney disease | | | | |
2014-000157-37: A study to examine whether the glucose lowering medicine dapagliflozin decreases urinary protein excretion and to determine the variation in response to dapagliflozin in plasma glucose / urinary protein excretion / blood pressure between and within patients. Het effect van dapagliflozine op de eiwituitscheiding en variabiliteit in response bij patiënten met type 2 diabetes. |
|
|
| Ongoing | 4 | 36 | Europe | Dapagliflozin, BMS-512148, | University Medical Center Groningen, University Medical Centre Groningen, Bristol Myers Squibb | Patients with type 2 diabetes and albuminuria between 100 and 3500 mg/g. Patineten met type 2 diabetes en albuminurie tussen 100 en 3500 mg/g | | | | |
2013-004042-42: This study aims to investigate the potential beneficial effects on the kidney of a new medication called Dapagliflozin in type 2 diabetic patients. |
|
|
| Ongoing | 4 | 40 | Europe | Dapagliflozin, Ramipril, Dapagliflozin, Dapagliflozin | King’s College London, Guy\'s and St Thomas NHS Foundation Trust, Bristol-Myers Squibb Pharmaceuticals Limited | Diabetic Nephropathy | | | | |
2014-003788-39: Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects with Type 2 Diabetes Mellitus on Previous Metformin Treatment |
|
|
| Ongoing | 4 | 24 | Europe | Forxiga, Onglyza, Forxiga, Onglyza | Profil Mainz GmbH & Co KG, Astra Zeneca | Type 2 Diabetes mellitus | | | | |
2014-002370-36: Glucose Control during glucocorticoid therapy in acute exacerbation of chronic obstructive pulmonary disease Behandeling van hoge bloedsuiker tijdens gebruik van glucocorticoïde medicijnenvoor een exacerbatie COPD |
|
|
| Ongoing | 4 | 46 | Europe | Forxiga, Forxiga | Slotervaart Hospital, AstraZeneca | Glucocorticoid induced hyperglycemia Glucocorticoid geinduceerde hyperglycemie | | | | |
2015-005034-21: Effets de la Dapagliflozine sur les modifications des lipides chez des patients diabétiques de type 2 |
|
|
| Ongoing | 4 | 26 | Europe | Forxiga, Dapagliflozine, Film-coated tablet, Forxiga | CHU de DIJON, Astrazeneca | diabète de type 2, diabète de type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Ongoing | 4 | 120 | Europe | Dapagliflozin (BMS512148) 10mg filmcoated tablet, Exentatide XS (Bydureon 2mg), EU/1/12/795/002; EU/1/12/795/007, EU/1/11/696/001 or EU/1/11/696/002, Tablet, Powder and solvent for prolonged-release suspension for injection, Dapagliflozin 10mg filmcoated tablet, Exenatide | University of Liverpool | Type 2 Diabetes Mellitus, Type II Diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2015-002094-38: The Effect of a SGLT2 inhibitor on glucose and ketone production following insulin wirhdrawal |
|
|
| Ongoing | 4 | 24 | Europe | Dapagliflozin, EMEA/H/C/002322, Tablet, Forxiga | University of Surrey, Astra Zeneca, Diabetes UK | In people who are insulin deficient: i.e have type1 or type 3c diabetes, In people who do not make enough insulin, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2016-005140-41: A study of the acute and chronic effects of dapagliflozin plus saxagliptin addition versus single addition of saxagliptin or dapagliflozin on glucose metabolism in patients with type 2 diabetes poorly controlled with metformin Uno studio sugli effetti acuti e cronici dell¿associazione di saxagliptin con dapagliflozin in rispetto all¿aggiunta del singolo componente sul metabolismo glucidico in pazienti con diabete tipo 2 in scarso controllo in trattamento con metformina |
|
|
| Ongoing | 4 | 45 | Europe | FORXIGA, ONGLYZA, FORXIGA, ONGLYZA, Film-coated tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE, ONGLYZA - 5 MG-COMPRESSE RIVESTITE CON FILM -USO ORALE-BLISTER NON PERFORATO CALENDARIZZATO (ALU/ALU) 28 COMPRESSE | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, ASTRAZENECA SPA, Dip. Univ. Medicina clinica e sperimentale Pisa | Patients with type 2 diabetes poorly controlled with metformin Pazienti con diabete tipo 2 in scarso controllo in trattamento con metformina, Patients with type 2 diabetes Pazienti con diabete tipo 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2016-004878-17: The effect of SGLT2 inhibitors in people with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 18 | Europe | Forxiga, EMEA/H/C/002322, Tablet, Forxiga | University of Leicester, Astra Zeneca Ltd | Type 2 diabetes., People with hyperglycaemia related diabetes. | | | | |
ChiCTR1800018292: Study for the effect of dapagliflozin combined with insulin pump in type 2 diabetes mellitus |
|
|
| Recruiting | 4 | 87 | | dapagliflozin 10mg/d+ insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d ;insulin pump + Saxagliptin 5mg/d or Liraglutide 1.2mg/d. | Teda International Cardiovascular Hospital; Teda International Cardiovascular Hospita, Tianjin Binhai New Area Health and Family Planning Commission science and technology project | Diabetes | | | | |
2017-005136-41: SGLT-2 Inhibition, Metabolomics and Cardiovascular Disease Inhibición de SGLT-2, Metabolómica y Enfermedad Cardiovascular |
|
|
| Not yet recruiting | 4 | 60 | Europe | Tablet, Forxiga 10 mg | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS), AstraZeneca | Type 2 Diabetes mellitus Diabetes mellitus tipo 2, Type 2 Diabetes (adult diabetes) Diabetes tipo 2 (diabetes del adulto), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
ChiCTR1800015030: A Clinical Trial on Safety and effect of Dapagliflozin to Control Blood Glucose Levels in Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 4 | 35 | | add-on or replace dapagliflozin | Dept. Rheumatology, Renji Hospital South Campus; Level of the institution：, The Department's own expense | Systemic Lupus Erythematosus | | | | |
ChiCTR1800019724: Efficacy and safety of dapagliflozin and acarbose in type 1 diabetes mellitus |
|
|
| Not yet recruiting | 4 | 62 | | dapagliflozin 10mg qd ;Acarbose 50mg tid | Department of Endocrinology, the First Affiliated Hospital of Shantou University Medical College; The First Affiliated Hospital of Shantou University Medical College, Shantou University Medical College Clinical Research Enhancement Initiative | Type 1 diabetes mellitus | | | | |
ChiCTR1900025034: Effects of different OADs on intensive therapy of continuous subcutaneous insulin infusion treatment for type 2 diabetes |
|
|
| Recruiting | 4 | 90 | | Insulin+Metformin 1000mg bid ;Insulin+Dapagliflozin 10mg qd ;Insulin Lispro | The Third Affiliated Hospital of Guangzhou Medical University; The Third Affiliated Hospital of Guangzhou Medical University, Characteristic discipline of Endocrinology of the Third Affiliated Hospital of Guangzhou Medical University | Newly diagnosed type 2 diabetes mellitus | | | | |
ChiCTR1900026285: A Randomized Controlled Trial for Comparing the Effects of Dapagliflozin and Sitagliptin on Glucose Fluctuation and Control Measured by CGM in Chinese Type 2 Diabetes Mellitus |
|
|
| Recruiting | 4 | 30 | | Dapagliflozin ;Sitagliptin phosphate | First Affiliated Hospital of Harbin Medical University; First Affiliated Hospital of Harbin Medical University, The study was supported by the fund of the Scientific and Technological innovation Program of the first affiliated hospital of Harbin medical university (YJSSJCX2018-16HYD) | Diabetes | | | | |
ChiCTR1900022751: Efficacy of Dapagliflozin and Acarbose in Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin Monotherapy: A Multi-centre Randomized Controlled trial |
|
|
| Recruiting | 4 | 128 | | Dapagliflozin(Anda don) 10mg once after breakfast increase Metfomin 500mg twice after breakfast and dinner,if glucose controls poor,metformin can be added to 1000mg twice after breakfast and dinner. ;Acarbose (Bai Tang) 50 mg three times at the same time of three meals increase Metfomin 500mg twice after breakfast and dinner,if glucose controls poor,metformin can be added to 1000mg twice after breakfast and dinner and Acarbose can be added to 100mg three times at the same time of | Zhujiang Hospital, Southern Medical University; Zhujiang Hospital, Southern Medical University, Self-financing | Type 2 diabetes | | | | |
ChiCTR1800015822: Effects of dapagliflozin combined with intensive insulin therapy on beta cell function in patients with newly diagnosed type 2 diabetes mellitus |
|
|
| Recruiting | 4 | 60 | | dapagliflozin+intensive insulin therapy ;intensive insulin therapy | Tungwah Hospital of Sun Yat-sen University; Tungwah Hospital of Sun Yat-sen University, Dongguan science and technology project (201850715046822). | Newly diagnosed type 2 diabetes mellitus | | | | |
ChiCTR1900023470: Study for dapagliflozin on glomerular hyperfiltration and visceral fat redistribution in patients with newly diagnosed type 2 diabetes mellitus |
|
|
| Not yet recruiting | 4 | 50 | | Dapagliflozin ;Acarbose | Tianjin Metabolic Diseases Hospital; Tianjin Metabolic Diseases Hospital, Self-financing | Type 2 Diabetes Mellitus | | | | |
2019-004586-41: Dapagliflozin, Exercise Training and physicAl function: the DETA trial. |
|
|
| Ongoing | 4 | 140 | Europe | Forxiga, Not applicable, Coated tablet, Forxiga | University of Leicester, AstraZeneca | Frailty and the preceding 'pre-frail' state in patients with type 2 Diabetes Mellitus., Type 2 Diabetes Mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Not yet recruiting | 4 | 50 | | Taking placebo 2 weeks ;Taking 10 mg dapagliflozin 2 weeks | Weishan People's Hospital, Shandong; Weishan People's Hospital, Shandong, self-raised | Uric acid | | | | |
2019-002046-20: Effects of dapagliflozin inhibition on the mechanisms of cardiac damage in the diabetic patient with HFpEF.-CARDIA-STIFF Efectos de la dapagliflozina sobre los mecanismos de la insuficiencia cardiaca con fracción de eyección preservada del paciente diabético”-CARDIA-STIFF |
|
|
| Not yet recruiting | 4 | 62 | Europe | Coated tablet, Forxiga 10 mg | Fundación para la Innovación en Biomedicina-FIBMED, Instituto de Salud Carlos III, Fundación para la Investigación Biomédica del Hospital Gregorio Marañón-FIBHGM | Patients with Diabetes mellitus type 2 and Heart Failure with preserved Ejection Fraction. pacientes con diabetes de tipo 2 e insuficiencia cardíaca con fracción de eyección preservada, Diabetic patients with Heart failure Pacientes diabéticos con insuficiencia cardíaca, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR1800016902: A randomized controlled study of metformin combined with insulin add different mechanismsoral hypoglycenmic drugs in type 2 diabetes |
|
|
| Not yet recruiting | 4 | 240 | | insulin combined with metformin and Sitagliptin therapy ;insulin combined with metformin and dapagliflozin therapy ;insulin combined with metformin and pioglitazone therapy | Armed Police Hospital of Chongqing; Armed Police Hospital of Chongqing, the Science and Technology key Program of Health Bureau of Chongqing, Armed Police Hospital of Chongqing | type 2 diabetes mellitus | | | | |
ChiCTR1900027931: The effect of sodium-glucose cotransporter 2 inhibitor on retinal vascular pressure in type 2 diabetes with early diabetic kidney disease |
|
|
| Not yet recruiting | 4 | 60 | | dapagliflozin combined with conventional therapy ;conventional therapy | Endocrine Department, People's Hospital of Tianjin; People's Hospital of Tianjin, None | type 2 diabetes with early diabetic kidney disease | | | | |
ChiCTR2100047733: Dapagliflozin rescues vasculogenic capacity of endothelial progenitor cells in diabetes |
|
|
| Completed | 4 | 30 | | Dapagliflozin | Department of Hypertension and Vascular Disease, the First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat sen University, Department of hypertension and vascular disease | Diabetes mellitus | | | | |
2019-004557-92: Sodium-glucose cotransporter-2 inhibition and renal oxygenation in type 1 diabetes |
|
|
| Not yet recruiting | 4 | 30 | Europe | Dapagliflozin, Film-coated tablet, Forxiga | Steno Diabetes Center Copenhagen, Novo Nordisk Fonden | Type 1 diabetes, Type 1 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
PDCED, ChiCTR2000041466: The preventive effect of dapagliflozin on cardiovascular events in diabetic population based on natriuretic peptide selection |
|
|
| Recruiting | 4 | 300 | | Standard treatment and dapagflozin ;Standard treatment | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Government funding | diabetic mellitus | | | | |
| Active, not recruiting | 4 | 30 | RoW | Dapagliflozin | The University of Hong Kong | Type2 Diabetes, Heart Failure With Reduced Ejection Fraction | 03/21 | 09/21 | | |
2020-001247-12: 2-week Dapagliflozin therapy effect on sodium elimination in patients with type 2 diabetes mellitus and renal disease |
|
|
| Not yet recruiting | 4 | 17 | Europe | Tablet, Forxiga | University Medical Center Groningen, University Medical Center Groningen | Type 2 diabetes mellitus (T2DM) with impaired renal function, Type 2 diabetes mellitus with renal disease, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-004929-23: Individual urinary protein decreasing effects of dapagliflozin in a remote clinical trial in patients with type 2 diabetes mellitus and elevated urinary protein concentrations. Individuele effecten van dapagliflozine op de hoeveelheid eiwit in urine in een klinisch onderzoek in de thuissituatie in patiënten met suikerziekte en een verhoogde hoeveelheid eiwit in de urine. |
|
|
| Not yet recruiting | 4 | 20 | Europe | Dapagliflozin, Film-coated tablet, Forxiga | University Medical Center Groningen, University Medical Center Groningen, AstraZeneca, Dutch Kidney Foundation | Patients with type 2 diabetes and albuminuria >20 mg/g (2.26 mg/mmol) Patiënten met type 2 diabetes en albuminurie >20 mg/g (2.26 mg/mmol), Type 2 diabetes Suikerziekte, Diseases [C] - Hormonal diseases [C19] | | | | |
@HOME, NCT06374043: Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. |
|
|
| Completed | 4 | 20 | Europe | Dapagliflozin 10mg Tab, Forxiga, (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, A10BK01, Placebo, Withings BPM Connect, Withings Body+, Hem-Col Capillary Blood Collection Device, MEMS (Medication Electronic Monitoring System) Cap, Questionnaire: participants' perspectives toward remote data collection | University Medical Center Groningen, AstraZeneca | Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Chronic Kidney Diseases, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, CKD, Proteinuria | 09/22 | 09/22 | | |
ChiCTR1900020955: A randomized controlled study for dapagliflozin reversed left ventricular hypertrophy in patients with type 2 diabetes mellitus |
|
|
| Not yet recruiting | 4 | 60 | | Dapagliflozin 10mg qd with or without non-glp-1 RA ;Drug therapy except Dapagliflozin and glp-1 RA | People Hospital of Nanhai District in Foshan; People Hospital of Nanhai District in Foshan, Self-financing | Diabetes mellitus | | | | |
2018-003283-31: Effects of 2 Weeks treatment with Dapagliflozin in subjects with an Impaired Glucose Homeostasis on Nocturnal substrate oxidation |
|
|
| Not yet recruiting | 4 | 17 | Europe | Dapagliflozin, Film-coated tablet, Forxiga | School of Nutrition and Translational research in Metabolism (NUTRIM), Maastricht University, AstraZeneca AB | Study to investigate the effect of dapagliflozin treatment on nocturnal substrate oxidation in overweight and obese subjects with a disrupted glucose homeostasis, Effect of dapagliflozin treatment on the switch between carbohydrate and lipid oxidation during the night, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
ChiCTR1900021490: The effect of one-week sequential treatment of dapagliflozin combined with long acting insulin after one-week intensive insulin therapy |
|
|
| Recruiting | 4 | 30 | | Phase I: Intensive insulin pump therapy; Phase II: Dapagliflozin combined with long acting insulin | The Third Affiliated Hospital of Guangzhou Medical University; The Third Affiliated Hospital of Guangzhou Medical University, Initial Funding for Doctor of The Third Affiliated Hospital of Guangzhou Medical University | Type 2 diabetes | | | | |
ChiCTR1900025357: A randomized open parallel controlled study for reversing diabetes by reducing liver fat deposition |
|
|
| Not yet recruiting | 4 | 600 | | basic medication + Dapagliflozin ;basic medication + Acarbose | The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, Self-raising | type 2 diabetes | | | | |
NCT06383832: Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet. |
|
|
| Completed | 4 | 36 | RoW | Dapagliflozin | Sun Jia | Overweight, Carbohydrate, Sodium-glucose Transporter 2 Inhibitors | 12/23 | 12/23 | | |
2021-003310-39: Effect of the antidiabetic drug dapagliflozin on the coronary function in type 2 diabetic patients. |
|
|
| Not yet recruiting | 4 | 100 | Europe | Tablet, Forxiga | CHU Saint Pierre, Cardiology Department CHU Saint Pierre, Brussels | Coronary macrovascular and microvascular function of type 2 diabetic patients with stable coronary artery disease and acute coronary syndrome (excluding ST elevation myocardial infarction)., Coronary function of type 2 diabetic patients with stable coronary artery disease and acute coronary syndrome (excluding ST elevation myocardial infarction)., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR1900023745: READ Study: A Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Assess the Effect of Dapagliflozin add-on Intensive Lifestyle Intervention for Remission of Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 4 | 328 | | dapagliflozin plus intensive lifestyle intervention ;lifestyle intervention | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, AstraZeneca Investment (CHINA) Co., Ltd. | Type 2 Diabetes | | | | |
2021-001167-24: Comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. Confronto tra farmaci inibitori di SGLT-2 in pazienti anziani affetti da diabete tipo 2. |
|
|
| Not yet recruiting | 4 | 1167 | Europe | Dapagliflozin, Canagliflozin, Empagliflozin, [Dapagliflozin], [Canagliflozin], [Empagliflozin], Film-coated tablet | SID - Società Italiana di Diabetologia e Malattie del Metabolismo, AIFA - Italian Medicines Agency | Type 2 diabetes mellitus Diabete mellito di tipo 2, diabetes Diabete, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2017-004889-10: Dapagliflozin effect on generation of red blood cells and physical fitness in patients with type 2 diabetes - a randomized, double-blind, controlled, parallel group, exploratory study Dapagliflozin effect on generation of red blood cells and physical fitness in patients with type 2 diabetes - a randomized, double-blind, controlled, parallel group, exploratory stud |
|
|
| Not yet recruiting | 4 | 75 | Europe | Forxiga, Film-coated tablet, Tablet, Forxiga, HCT Hexal | University Hospital Tuebingen, AstrZeneca GmbH | Patients with T2DM and hypertension aged 40 to 70 years (including) Patienten mit Diabetes mellitus Typ 2 im Alter von 40 bis 70 Jahren (einschließlich), Patients with T2DM and hypertension aged 40 to 70 years (including) Patienten mit Diabetes mellitus Typ 2 und Bluthochdruck im Alter von 40 bis 70 Jahren (einschließlich), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
DAPA-MEMS, NCT04570865: Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS® |
|
|
| Not yet recruiting | 4 | 100 | US | Dapagliflozin, CardioMEMS | Scripps Health | Heart Failure, Systolic | 12/21 | 02/22 | | |
NCT04090580: Impact on Glycemic Variability After Treatment With Dapagliflozin on Type 2 Diabetes Patients |
|
|
| Recruiting | 4 | 88 | RoW | Continuous glucose monitoring | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, AztraZeneca | Type 2 Diabetes | 12/21 | 12/21 | | |
ChiCTR1900028227: Construction of efficacy prediction model for dapagliflozin with genetic variation combined with serum metabolites |
|
|
| Not yet recruiting | 4 | 100 | | dapagliflozin | Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Sixth People's Hospital, Hospital level scientific research fund of Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Type 2 diabetes | | | | |
ChiCTR2000036076: Comparison of the efficacy and safety of pioglitazone/metformin (FDC) in combination with dapagliflozin therapy versus basal insulin in combination with metformin therapy in patients with inadequately controlled type 2 diabetes mellitus |
|
|
| Not yet recruiting | 4 | 150 | | pioglitazone-metformin (FDC) + dapagliflozin ;basal insulin + metformin | Shanghai General Hospital; Hangzhou Sino-US East China Pharmaceutical Co., Ltd, Hangzhou Sino-US East China Pharmaceutical Co., Ltd | type 2 diabetes | | | | |
PRODAPA-CKD, NCT06281899: Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 4 | 200 | Europe | Dapagliflozin 10 mg Tab, Low protein diet | Anemia Working Group Romania, Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania, Dr Carol Davila Teaching Hospital of Nephrology, Nephrology Department, Bucharest, Romania, Carol Davila University of Medicine and Pharmacy | Chronic Kidney Diseases, Type 2 Diabetes Mellitus | 12/24 | 03/25 | | |
2021-000995-13: Effects of Dapagliflozin on CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD) Effekten af dapagliflozin på hjertets struktur og funktion hos patienter med kronisk nyresygdom |
|
|
| Ongoing | 4 | 222 | Europe | Forxiga, Tablet, Forxiga | Department of Cardiology, Herlev and Gentofte hospital, Novo Nordisk Foundation, Gentofte hospital | Chronic kidney disease Kronisk nyresygdom, Chronic kidney disease Kronisk nyresygdom, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
EVOMETA, NCT04706637: A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin |
|
|
| Not yet recruiting | 4 | 120 | RoW | Evogliptin, Dapagliflozin | Kyung Hee University Hospital at Gangdong, Dong-A ST Co., Ltd. | Bone Diseases, Metabolic, Diabetes Mellitus, Type 2 | 01/22 | 01/23 | | |
2021-001661-21: Feasibility of aggressively lowering urine albumin in individuals with kidney biopsy-proven diabetic kidney disease - A Pilot Study |
|
|
| Not yet recruiting | 4 | 20 | Europe | Tablet, Injection, Forxiga, Jardiance, Ozempic, Telmisartan, Losartan, hydrochlorthiazide, Spironolactone, Trental, Olumiant, Kerendia, Rybelsus | Herlev and Gentofte Hospital, Herlev and Gentofte Hospital | Diabetic Kidney Disease, Kidney Disease due to diabetes mellitus type 2, Diseases [C] - Hormonal diseases [C19] | | | | |
2021-005394-66: Effects of Dapagliflozin on cardiac deformation and clinical outcomes in heart failure with reduced and mildly reduced ejection fraction Effetti del Dapagliflozin sulla deformazione cardiaca e sugli esiti clinici nello scompenso cardiaco con frazione di eiezione ridotta e lievemente ridotta |
|
|
| Not yet recruiting | 4 | 88 | Europe | Dapagliflozin, [Dapagliflozin], Film-coated tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE, ASTRAZENECA | heart failure with left ventricular ejection fraction <50% insufficienza cardiaca con frazione di eiezione ventricolare sinistra < 50%, heart failure with reduced or mildly reduced left ventricular ejection fraction insufficienza cardiaca con frazione di eiezione ventricolare sinistra ridotta o moderatamente ridotta, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04620590: An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function |
|
|
| Recruiting | 4 | 17 | Canada | Dapagliflozin 10 MG [Farxiga] | George Clinical Pty Ltd, University Medical Center Groningen, Ground Zero Pharmaceuticals | Diabetes Mellitus, Type 2, Impaired Renal Function | 03/22 | 04/22 | | |
2019-000979-16: Dapagliflozin effect in the reduction of abdominal fat layers in type 2 diabetic patients. Efecto de dapagliflozina en la reducción de la grasa abdominal en pacientes diabéticos tipo 2. |
|
|
| Not yet recruiting | 4 | 88 | Europe | Tablet, Metformin, Dapagliflozin | Dr. Guillem Cuatrecasas - CPEN S.L., AstraZeneca Farmacéutica Spain, S.A. | Abdominal fat layers in type 2 diabetic patients Reducción de la capa de grasa omental en pacientes con diabetes tipo 2, Abdominal fat layers in type 2 diabetic patients Reducción de la capa de grasa omental en pacientes con diabetes tipo 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT03331289: Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria |
|
|
| Completed | 4 | 107 | US | Placebo, Placebo drug, Exenatide, Byetta, Bydureon, Dapagliflozin, Farxiga, Exenatide and Dapagliflozin, Byetta plus Dapagliflozin | The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 2 | 03/22 | 11/22 | | |
ChiCTR2100044600: Pharmacokinetic and Pharmacodynamic Properties of Dapagliflozin in patients with stage 4 chronic kidney disease |
|
|
| Recruiting | 4 | 24 | | single-dose of dapagliflozin 10mg ; dapagliflozin 10mg daily for 5 consecutive days | Nanfang Hospital of Soutnern Medical University; Nanfang Hospital of Soutnern Medical University, 2020ZX09201-017 | stage 4 chronic kidney disease | | | | |
2022-000740-29: A comparison of two drugs for treating patients with Chronic Kidney Disease and protein in the urine En sammenligning af to lægemidler til behandling af patienter med Kronisk Nyresygdom og protein i urinen |
|
|
| Ongoing | 4 | 20 | Europe | Spironolactone, Dapagliflozine, Tablet | Department of Renal Medicine, Aarhus University Hospital, Henrik Birn | Chronic Kidney Disease with albuminuria Kronisk Nyresygdom med albuminuri, Chronic Kidney Disease with protein in the urine Kronisk Nyresygdom med protein i urinen, Not possible to specify | | | | |
NCT02981966: Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects |
|
|
| Completed | 4 | 32 | US | Dapagliflozin, Farxiga, Placebo | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 04/22 | 05/23 | | |
NCT06326034: Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients |
|
|
| Completed | 4 | 40 | RoW | Dapagliflozin | Mohammed Mahmood Mohammed | Diabetic Nephropathy Type 2 | 01/23 | 01/23 | | |
NCT04340908: Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery |
|
|
| Recruiting | 4 | 500 | RoW | Dapagliflozin 10 MG, Forxiga, Placebos | Hongchang Guo | Diabetes Mellitus, Type 2, Cardiac Surgery | 06/22 | 06/23 | | |
ChiCTR2000040135: To observe the effect of dapagliflozin on serum uric acid in Type 2 Diabetes Mellitus |
|
|
| Recruiting | 4 | 100 | | Dapagliflozin ;Glimepiride | Weishan People's Hospital; Weishan People's Hospital, self-raised | Diabetes | | | | |
NCT02981069: Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM |
|
|
| Completed | 4 | 90 | US | Dapagliflozin, Farxiga, Exenatide, Byetta, Bydureon, Placebo | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 07/22 | 03/23 | | |
NCT04743453: EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS. |
|
|
| Recruiting | 4 | 220 | RoW | Dapagliflozin, Placebo | University of Sao Paulo General Hospital, Federal University of São Paulo | Kidney Transplantation, Diabetes Mellitus, Type 2, Diabetes Complications | 08/22 | 08/23 | | |
| Completed | 4 | 5 | RoW | Dapagliflozin 10Mg Tab | University of Campinas, Brazil | End-stage Renal Disease | 09/22 | 10/22 | | |
ChiCTR2100054612: Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and nonalcoholic fatty liver disease |
|
|
| Recruiting | 4 | 84 | | Dapagliflozin ;Other anti-diabetic drugs | Xinqiao Hospital of Army Medical University; Xinqiao Hospital of Army Medical University, Self-raised | Type 2 diabetes and nonalcoholic fatty liver disease | | | | |
ChiCTR2100052426: Impact of Dapagliflozin on the sympathetic activity in chronic heart failure with reduced ejection fraction: Rationale and design of the randomized, double-blind, palcebo controlled trial |
|
|
| Not yet recruiting | 4 | 120 | | Dagliazin was taken orally 10mg/ day ;Oral placebo was taken orally 10mg/ day | The First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University, Self-raised funds | chronic heart failure | | | | |
NCT05797935: Evaluation of Changes in Pancreatic Fat Content Using Advanced MR Sequences in Diabetics on Dapagliflozin Therapy |
|
|
| Completed | 4 | 50 | RoW | Dapagliflozin 10mg Tab | Postgraduate Institute of Medical Education and Research | Pancreatic Lipomatosis | 12/22 | 12/22 | | |
| Recruiting | 4 | 62 | Europe | Dapagliflozin 10 MG [Farxiga], Placebo | Hospital General Universitario Gregorio Marañon, University of Navarra, Instituto de Salud Carlos III, Fundación para la Investigación Biomédica del Hospital Gregorio Maranon | Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction | 12/22 | 12/22 | | |
ChiCTR2000036769: A multicenter, randomized, parallel controlled, open-label study on the effects of SGLT2 inhibitor on the renal prognosis of patients with chronic kidney disease with type 2 diabetes |
|
|
| Recruiting | 4 | 300 | | SGLT2i (Dapagliflozin), 5mg qd p.o. ;GLP-1RA (liraglutide), 18 mg/bottle, dosage: once a day, 0.6 mg each time, subcutaneous injection; if there are no obvious adverse reactions, increase to once a day, 1.2 mg each time, before breakfast in the second week Subcutaneous injection; plus dapagliflozin 5mg qd po ;Only use ACEI/ARB, CCB and other antihypertensive drugs, and other antihypertensive drugs | Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 2020 Shenkang Precision Diagnosis and Treatment Project for Intractable Diseases | Diabetic Nephropathy | | | | |
ChiCTR2000035387: A prospective, randomized, controlled trial for the efficacy and safety of improving left ventricular remodeling in combined use of sacubitril-valsartan and dapagliflozin compared to RAAS inhibitors in very elderly patients with acute myocardial infarction at the early stage of hospitalization |
|
|
| Not yet recruiting | 4 | 150 | | sacubitril-valsartan and dapagliflozin ;RAAS inhibitors | HuaDong Hospital; HuaDong Hospital, The second round of The Three-year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals of Shanghai Shenkang Hospital Development Center | acute myocardial infarction | | | | |
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 600 | | DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin) | Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project | Type 2 diabetes | | | | |
NCT05225077: Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients |
|
|
| Recruiting | 4 | 600 | RoW | Dapagliflozin 10 MG [Farxiga] | Dong-A University | Renal Insufficiency, Chronic, Cardiac Catheterization, Percutaneous Coronary Intervention | 12/22 | 12/23 | | |
| Active, not recruiting | 4 | 328 | RoW | Intensive lifestyle intervention, Dapagliflozin 10 MG Oral Tablet, Placebo Oral Tablet | Shanghai Zhongshan Hospital | Type 2 Diabetes | 01/23 | 06/23 | | |
2021-002813-33: Dapaglifozin use in patients with heart failure during acute myocardial infarction Utilizzo di dapaglifozin per il trattamento di pazienti con scompenso cardiaco durante infarto miocardico acuto. |
|
|
| Not yet recruiting | 4 | 140 | Europe | FORXIGA, [A10BX09], Coated tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE | AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA, Univeristà del Piemonte Orientale | Patients with type 2 diabetes and ST-elevation myocardial infarction treated with primary primary percutaneous coronary intervention and reduced left ventricle ejection fraction. Pazienti con diabete mellito di tipo 2 ed infarto miocardico acuto con sopraslivellamento del tratto ST trattati con angioplastica primaria e ridotta funzione ventricolare sinistra., Diabetic patients with acute myocardial infarction and reduced cardiac function Pazienti con diabete ed infarto miocardico acuto trattato e ridotta funzionalità cardiaca, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2022-002428-10: CAN DAPAGLIFLOZIN PRESERVE STRUCTURE AND FUNCTION IN TRANSPLANTED KIDNEYS? |
|
|
| Ongoing | 4 | 330 | Europe | dapagliflozin, Tablet, Forxiga (dapagliflozin) | Oslo Univeristy Hospital - Rikshospitalet, AstraZeneca | Kidney transplanted patients. Looking at the effect of SGLT2 inhibitor on graft survival by repeated eGFR measurements, measured GFR, kidney graft biopsies to evaluate inflammation, fibrosis and vascular pathology. As secondary endpoints, we will look at the effect of visceral fat accumulation and blood pressure., Kidney transplanted patients. Looking at the effect of SGLT2 inhibitor on kidney graft survival and preserved function of the kidney., Diseases [C] - Symptoms and general pathology [C23] | | | | |
NCT06127433: The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes |
|
|
| Recruiting | 4 | 210 | RoW | Insulin Glargine, Metformin, Dapagliflozin, Insulin aspart | Sun Yat-sen University | Insulin Pump，Continuous Glucose Monitoring Technology | 05/24 | 12/24 | | |
2022-002453-25: Study of the effects of sodium-glucose cotransporter 2 inhibitors on kidney function in patients undergoing cardiac surgery Studie naar effect van sodium-glucose cotransporter-2 inhibitoren op nierfunctie in patiënten die een hartoperatie ondergaan |
|
|
| Ongoing | 4 | 784 | Europe | Film-coated tablet, Forxiga | Amsterdam UMC, Netherlands Organisation for Health Research and Development | Cardiac Surgery-Associated Acute Kidney Injury cardiochirurgie geassocieerde nierinsufficiëntie, Kidney failure following cardiac surgery Nierschade optredend na hartoperaties, Diseases [C] - Symptoms and general pathology [C23] | | | | |
ChiCTR2300072707: Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodellilng in patients with type 2 diabetes and HFrEF |
|
|
| Completed | 4 | 60 | | Patients received dapaglifozin 10 mg once daily for 1 year ;Patients received placebo once daily for 1 year | Jiangxi Provincial People's Hospital; Jiangxi Provincial People's Hospital, the Science and Technology Project of Health Commission of Jiangxi Province | Heart Failure | | | | |
| Active, not recruiting | 4 | 1020 | Europe | Dapagliflozin 10 MG | Spanish Society of Cardiology, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | Aortic Stenosis, Transcatether Aortic Valve Implantation | 12/24 | 12/24 | | |
ChiCTR2200055897: Dapagliflozin in Patients with Severe Reduced Ejection Fraction Heart Failure - A Multicenter Registry Study |
|
|
| Recruiting | 4 | 1000 | | None | The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, None | Heart Failure | | | | |
DAPA-AF, NCT04792190: Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation |
|
|
| Completed | 4 | 25 | US | dapagliflozin, Placebo | University of Rochester, AstraZeneca | Atrial Fibrillation | 03/23 | 06/23 | | |
ChiCTR2100049834: Efficacy of dapagliflozin in the treatment of HFrEF with moderate to severe obstructive sleep apnea syndrome: a prospective, randomized controlled clinical study |
|
|
| Not yet recruiting | 4 | 30 | | dapagliflozin ;Standard optimized treatment of heart failure | Zhongda Hospital, Affliated to Southeast University; Zhongda Hospital, Affliated to Southeast University, self-funded | Heart failure with obstructive sleep apnea syndrome | | | | |
ChiCTR2200058174: Efficacy and safety of dapagliflozin in patients with primary nephropathy treated with glucocorticoids: A pilot study |
|
|
| Not yet recruiting | 4 | 264 | | Dapagliflozin ;None | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Self-funded by researchers | Nephropathy | | | | |
| Recruiting | 4 | 178 | RoW | Dapagliflozin | China National Center for Cardiovascular Diseases | Diabetes Mellitus, Type 2, Cardiac Surgery | 06/23 | 07/23 | | |
ChiCTR2200065869: Effects of dapagliflozin on circulating endothelial progenitor cells and vascular lesions in type 2 diabetes mellitus |
|
|
| Not yet recruiting | 4 | 90 | | Dapagliflozin ;Dura glycopeptide ;Dapagliflozin + Dura glycopeptide | The First Affiliated Hospital of Chengdu Medical College; The First Affiliated Hospital of Chengdu Medical College, Special Fund of Key Discipline Laboratory of Sichuan Province | Type 2 diabetes | | | | |
NCT06417320: Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years |
|
|
| Recruiting | 4 | 60 | RoW | ACEI, SGLT-2i, Captopril, forxiga | Mansoura University | Nephrotic Syndrome in Children | 01/25 | 08/25 | | |
ChiCTR2200067020: Clinical efficacy and safety study of SGLT-2 inhibitor dagliflozin to improve cognitive dysfunction in combination with type 2 diabetes |
|
|
| Recruiting | 4 | 102 | | Oral dapagliflozin ;no | The Second Affiliated Hospital of Anhui Medical Sciences; The Second Affiliated Hospital of Anhui Medical Sciences, 2021 Key Projects of Clinical Research Fund of the Second Affiliated Hospital of Anhui Medical University | Type 2 diabetes | | | | |
NCT02616666 / 2015-001873-42: A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients |
|
|
| Active, not recruiting | 4 | 632 | Europe | Dapagliflozin, FORXIGA, Standard of Care | University of Liverpool, AstraZeneca, Clinical Practice Research Datalink | Type 2 Diabetes Mellitus | 07/24 | 07/24 | | |
ChiCTR2100047856: The benefit of dapagliflozin on cardiorespiratory fitness in coronary heart disease patients with type 2 diabetes undergoing percutaneous coronary intervention |
|
|
| Recruiting | 4 | 120 | | standardized medication, including antiplatelet, beta blockers, angiotensin II receptor blockers, statins，antidiabetic agents exclusive of dapagliflozin, and so on. ;standardized medication, including antiplatelet, beta blockers, angiotensin II receptor blockers, statins，antidiabetic agents inclusive of dapagliflozin, and so on. | Yuebei People's Hospital; Yuebei People's Hospital, Shaoguan health research project(Y21052) &Guangdong province medical science and technology research fund project (B2021415)) &Self-raised | coronary artery disease | | | | |
ChiCTR2100052963: Effect of dapagliflozin on blood and urine biochemistry, electrolytes and bioelectrical impedance in patients with type 2 diabetes mellitus |
|
|
| Recruiting | 4 | 40 | | dapagliflozin 10mg | The First Affiliated Hospital of Nanjing Medical University; Jiangsu Provincial People's Hospital, Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) | Type 2 diabetes | | | | |
DEFORM, NCT05606718: Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling |
|
|
| Recruiting | 4 | 98 | RoW | Dapagliflozin, guideline-directed medical therapy (GDMT) | Sun Yat-sen University | Functional Mitral Regurgitation | 06/23 | 07/23 | | |
ChiCTR2200058691: The Effect of Dapagliflozin in Patient with Paroxysmal Atrial Fibrillation: A Prospective, Randomized, Blank Controlled, Single-Center Study |
|
|
| Not yet recruiting | 4 | 60 | | Dapagliflozin 10mg/day ;No intervention | Affiliated Drum Tower Hospital, Nanjing University School of Medicine; Affiliated Drum Tower Hospital, Nanjing University School of Medicine, Clinical Trial Funding from Nanjing Drum Tower Hospital | Atrial fibrillation | | | | |
2021-005721-25: SGLT2-Hemmung in Verbindung mit Lebensstilintervention und die Auswirkung auf das Risiko für Komplikationen bei Subtypen von PatientInnen mit Prädiabetes - eine randomisierte, placebokontrollierte, multizentrische Studie - |
|
|
| Not yet recruiting | 4 | 182 | Europe | Forxiga, Film-coated tablet, Forxiga | Univeristy Hospital Tuebingen, BMBF | The study will include adult male and female patients with an early stage of chronic kidney disease (CKD stage G1A2/G2A2) and prediabetes, The study will include adult male and female patients with an early stage of chronic kidney disease (CKD stage G1A2/G2A2) and prediabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT02911792: Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration |
|
|
| Completed | 4 | 72 | US | Dapagliflozin, Farxiga, Metformin, Metformin-XR, Glipizide 5 MG | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 07/23 | 07/23 | | |
| Recruiting | 4 | 50 | Europe | Dapagliflozin 10mg Tab | Monaldi Hospital | Dapagliflozin Adverse Reaction, Efficacy, Systemic Right Ventricle | 08/23 | 08/24 | | |
NCT06026787: Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome |
|
|
| Completed | 4 | 60 | RoW | Dapagliflozin 10mg Tab | Ain Shams University | Nephrotic Syndrome, Sodium-Glucose Transporter 2 Inhibitors | 08/23 | 08/23 | | |
| Not yet recruiting | 4 | 120 | | Dapagliflozin 10mg qd ;Tripterygium glycosidesin combination with Dapagliflozin | Yijishan Hospital of Wannan Medical College; Yijishan Hospital of Wannan Medical College, self-paying | diabetic nephropathy | | | | |
| Active, not recruiting | 4 | 3239 | Europe, US, RoW | theraputic heparin, unfractionated heparin, Enoxaparin, Dalteparin, Tinzaparin, Heparin, prophylactic heparin, enoxaparin, dalteparin, Fondparinux, P2Y12, Ticagrelor, Prasugrel, Clopidogrel, Crizanlizumab Injection, SGLT2 inhibitor, dapagliflozin, empagliflozin, canagliflozin, ertugliflozin | Matthew Neal MD, National Heart, Lung, and Blood Institute (NHLBI) | Covid19 | 08/23 | 06/24 | | |
NCT05541484: Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency |
|
|
| Recruiting | 4 | 20 | US | SGLT2 inhibitor, Dapagliflozin 10mg (Farxiga), Biosense Breath Ketone Analyzer | Washington University School of Medicine, Juvenile Diabetes Research Foundation | Diabetes Mellitus, Type 1 | 12/23 | 08/24 | | |
| Recruiting | 4 | 80 | Europe | Dapagliflozin, Forxiga, Placebo | Frank Ruschitzka, AstraZeneca | Heart Failure，Congestive | 12/24 | 12/24 | | |
NCT05748925: Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients |
|
|
| Active, not recruiting | 4 | 100 | RoW | dapagliflozin, placebo | Mansoura University | SLE, Lupus Nephritis, SGLT2 Inhibitors | 10/23 | 12/23 | | |
NCT05704088: SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients |
|
|
| Active, not recruiting | 4 | 100 | RoW | Dapagliflozin tablet, placebo | Mansoura University | SGLT2 INHIBITORS, Lupus Nephritis, BMD | 10/23 | 12/23 | | |